CAS: 13103-34-9; Boldenone Undecylenate

上下游产品

宝丹酮 1-Dehydrotestosterone 846-48-0
睾酮 Testosterone 58-22-0

睾酮置于4-二甲氨基吡啶,5-甲基吩嗪硫酸甲酯,Rhodococcus Erythropolis Wy 1406 3-Ketosteroid-δ1-Dehydrogenase,I51L/i350T Double Mutant,三乙胺体系中,用 二氯甲烷,二甲基亚砜 用作溶剂,化学反应 0.42H,反应生成宝丹酮十一烯酸酯
参考文献:通过单细胞生物催化 δ1-脱氢和 C17β-羰基还原级联合成代谢雄激素的批量和连续流不对称合成
标题:通过单细胞生物催化 δ1-脱氢和 C17β-羰基还原级联合成代谢雄激素的批量和连续流不对称合成
摘要:Chemoenzymatic Asymmetric Synthesis Of An Anabolic-Androgenic Steroid (+)-Boldenone (3) And Its Prodrug (+)-Boldenone Undecylenate (4) Was Accomplished Starting From Commercially Available 4-Androstene-3,17-Dione (4-Ad,1) Under Both Batch And Continuous Flow Conditions. The Key Feature Of The Current Synthesis Is The Construction Of An Enzymatic Cascade Process In A Single Escherichia Coli Cell For
Doi:10.1039/d2Gc04894A

专利信息

专利号:US-9303000-B2
优先权日:2011-01-17
标 题 :Olefin containing nuclear transport modulators and uses thereof
发明人：SANDANAYAKA VINCENT P; SHACHAM SHARON; SHECHTER SHARON; MCCAULEY DILARA
权利人:SANDANAYAKA VINCENT P; SHACHAM SHARON; SHECHTER SHARON; MCCAULEY DILARA; KARYOPHARM THERAPEUTICS INC
摘要:The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).

专利号:US-2025281509-A1
优先权日:2021-04-26
标 题 :Sequential hormone therapy to improve survival and enhance response to immune therapy in men with prostate cancer
发明人：DENMEADE SAMUEL R; ISAACS JOHN T; ANTONARAKIS EMMANUEL S; KACHHAP SUSHANT; MARKOWSKI MARK CHRISTOPHER
权利人:UNIV JOHNS HOPKINS
摘要:Disclosed are methods for treating men with castrate resistant prostate cancer with a sufficient dose of testosterone to achieve supraphysiologic serum levels of testosterone in sequence with androgen ablative treatment or androgen synthesis inhibitors for one or more cycles until evidence of radiographic progression, at which point the subject will receive immune checkpoint blockade therapy.

专利号:US-9550757-B2
优先权日:2010-03-05
标题:Nuclear transport modulators and uses thereof
发明人：SHACHAM SHARON; KAUFFMAN MICHAEL; SANDANAYAKA VINCENT P; SHECHTER SHARON
权利人:KARYOPHARM THERAPEUTICS INC
摘要:The invention generally relates to the field of nuclear transport modulators, e.g., CRM1 inhibitors, and more particularly to new substituted-heterocyclic azole compounds, the synthesis and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with CRM1 activity such as in treating cancer and other neoplastic disorders, inflammatory diseases, disorders of abnormal tissue growth and fibrosis including cardiomyopathy, pulmonary fibrosis, hepatic fibrosis, glomerulonephritis, and other renal disorders, and for the treatment of viral infections (both acute and chronic).

专利号:US-2014315720-A1
优先权日:2012-10-24
标 题 :Polysaccharide ester microspheres and methods and articles relating thereto
发明人：FALLON DENIS G; GARRETT THOMAS S; KIZER LAWTON E; ZAZZARA KAREN L; COMBS MICHAEL T; JOHNSON RICHARD K; DEHART GARY
权利人:CELANESE ACETATE LLC
摘要:A method for producing a polysaccharide ester microsphere may include forming a polysaccharide ester product from a polysaccharide synthesis, wherein the polysaccharide ester product comprises a polysaccharide ester and a solvent; diluting the polysaccharide ester product, thereby yielding a polysaccharide ester dope; and forming a plurality of polysaccharide ester microspheres from the polysaccharide ester dope. Suitable polysaccharides may include, but are not limited to, starch, cellulose, hemicellulose, algenates, chitosan, and any combination thereof. Esters thereof may be organic esters (e.g., acetate and the like), inorganic esters (e.g., sulfonates and the like), or combinations thereof. Further, the solids conent of the polysaccharide ester dope, in some instances, may be greater than about 16 wt %.